Pharmaniaga Mulls Changes in Business Strategy in China (Malaysia)
This article was originally published in PharmAsia News
Malaysia state-owned pharmaceutical company Pharmaniaga is reevaluating its China strategy after incurring a 21.5 million RM loss in fiscal 2006 at its Chinese operation. They blame the loss on escalating costs for distribution, and on changing pharmaceutical regulations in China. In 2005 Pharmaniaga purchased a 40 percent stake in China-based Wuxi Worldbest Treeful Pharmaceutical. Pharmaniaga's total fiscal 2006 net profit fell by over 100 percent compared to the previous year to a profit of 14 million RM, on 1.1 billion RM in revenue. Pharmaniaga Chairman Datuk Azman Yahya says the Chinese market remains promising and "big." (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.